Screener
Prime Medicine PRME Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | June 30,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 209,231 | 221,865 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,737,548 and 180,514,014 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 2 | 2 |
| Additional paid-in capital | 1,019,401 | 1,009,138 |
| Accumulated other comprehensive (loss) income | (9) | 82 |
| Accumulated deficit | (979,585) | (888,354) |
| Total stockholders’ equity | 39,809 | 120,868 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's common stock?
- Prime Medicine (PRME) reported common stock of 775M in Q2 2026.
- How has Prime Medicine's common stock changed year-over-year?
- Prime Medicine's common stock decreased by 0.0% year-over-year, from 775M to 775M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Prime Medicine's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude